Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Views & Analysis
eye-on-innovation betz-16x9-2

Merck KGaA celebrates 350 years of innovation

As part of pharmaphorum’s eye-on-innovation interview series, Paul Tunnah speaks to Merck Biopharma’s vice president of innovation Ulrich Betz on how the company is celebrating its 350th

Views & Analysis
Crowd of people gathering at center, men and women, different ethnic groups and clothing

Accelerating access for rare disease patients – the need to ...

Santhera is putting patient needs at the heart of its rare disease speciality business. Chief Executive Officer Thomas Meier, PhD, talks about the company’s mission – and how rationalising Europe’s drug review systems could help patients.

Sales & Marketing

Digital

Market Access

Market Access
Mumbai, India

What India can learn from Kinvard Bio

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network.

Editor's Picks

  1. Revolution's ASCO showstopper gets FDA greenlight
  2. Anthropic AI tool conducts physical scientific experiments
  3. UK MHRA authorises orforglipron private prescription
  4. Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321
  5. Sword Health buys Headspace in $200m to $300m deal

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

more

Patients

more

R&D

more